In the present study, therefore, we investigated the p-Smad2 expression in surgical resection specimens from NSCLC to evaluate the prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells for patients with clinical stage I to IIIA NSCLC. The gene discussed is SMAD2; the disease is cancer.